AI Driven Drug Discovery Market Forecasts to 2034 – Global Analysis By Component (Software and Services), Technology, Drug Type, Therapeutic Area, Application, End User and By Geography
According to Stratistics MRC, the Global AI Driven Drug Discovery Market is accounted for $4.2 billion in 2026 and is expected to reach $16.1 billion by 2034 growing at a CAGR of 17.5% during the forecast period. AI-driven drug discovery involves the application of artificial intelligence technologies such as machine learning, deep learning, and advanced data analytics to enhance and accelerate the development of new medicines. These technologies analyze large volumes of biological, chemical, and clinical data to identify promising drug targets, design and optimize molecular compounds, and evaluate drug safety and effectiveness. By automating complex research processes and uncovering patterns within extensive datasets, AI helps reduce the time, cost, and risk traditionally associated with pharmaceutical research and drug development.
Market Dynamics:
Driver:
Accelerating R&D timelines and cost pressures
The pharmaceutical industry faces immense pressure to reduce the substantial time and financial investment required to bring a drug to market, which traditionally exceeds a decade and costs over $2.6 billion. AI-driven platforms directly address this by automating target identification, predicting drug toxicity early, and optimizing clinical trial designs. Machine learning algorithms can analyze vast datasets in days rather than years, allowing companies to fail unsuccessful candidates faster and focus resources on the most promising assets. This imperative to improve R&D productivity is compelling pharmaceutical giants to integrate AI solutions across their discovery pipelines, transforming operational efficiency.
Restraint:
Data availability and interoperability challenges
The effectiveness of AI models is heavily dependent on the availability of high-quality, standardized, and annotated datasets. However, the biomedical data landscape is often fragmented, consisting of disparate electronic health records, proprietary chemical libraries, and unstructured research papers that lack interoperability. Concerns regarding data privacy, intellectual property rights, and the siloed nature of proprietary datasets further restrict the training of robust algorithms. Without access to comprehensive, clean, and harmonized data, AI models risk generating biased or inaccurate predictions, which limits their full potential and slows down mainstream adoption across the industry.
Opportunity:
Expansion into novel therapeutic modalities and complex diseases
As AI algorithms become more sophisticated, there is a significant opportunity to apply them beyond traditional small molecules to complex modalities such as gene therapies, RNA therapeutics, and antibody-drug conjugates. Generative AI and deep learning are unlocking the ability to design novel biologics and navigate the complexities of multi-target diseases like neurodegeneration and rare genetic disorders. The integration of multi-omics data (genomics, proteomics) with AI is enabling the discovery of entirely new classes of drugs that were previously undruggable. This capability opens vast new revenue streams for AI-focused firms and accelerates the development of cures for historically challenging therapeutic areas.
Threat:
Evolving regulatory and validation frameworks
The 'black box' nature of many AI algorithms poses a significant threat to widespread adoption, as regulatory bodies like the FDA and EMA grapple with how to validate and approve drugs discovered through opaque AI processes. There is currently a lack of standardized guidelines for verifying the safety, efficacy, and reproducibility of AI-generated drug candidates. Uncertainty surrounding intellectual property rights for AI-invented compounds further complicates commercialization strategies. As the market grows, any delays in establishing clear regulatory pathways or failures in AI-predicted candidates during late-stage trials could erode investor confidence and slow market momentum.
Covid-19 Impact
The COVID-19 pandemic served as a catalyst for the AI-driven drug discovery market, as researchers urgently sought rapid solutions. AI platforms were deployed extensively to repurpose existing drugs and design novel antivirals against the SARS-CoV-2 virus, significantly compressing the initial discovery phase. The crisis validated AI’s capability to operate at unprecedented speeds, leading to a surge in venture capital funding and strategic partnerships. However, supply chain disruptions and the redirection of clinical resources initially hampered validation efforts. Post-pandemic, the industry has adopted a more resilient mindset, leveraging the proven success of AI to build robust, agile discovery pipelines for future pandemics and chronic diseases.
The Machine Learning segment is expected to be the largest during the forecast period
The Machine Learning segment is expected to account for the largest market share during the forecast period, due to its foundational role in analyzing complex biological datasets. As the most mature AI technology, ML algorithms are extensively used for pattern recognition in genomics, protein folding, and biomarker identification. Its versatility allows for application across various stages, from target validation to preclinical modeling.
The Pharmaceutical Companies segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the Pharmaceutical Companies segment is predicted to witness the highest growth rate, driven by the urgent need to replenish patent-expired drug portfolios. Major pharma players are aggressively adopting AI to de-risk R&D, streamline operations, and lower the high attrition rates associated with clinical trials. The shift from in-house R&D to hybrid models involving strategic acquisitions of AI-native startups is accelerating adoption.
Region with largest share:
During the forecast period, the North America region is expected to hold the largest market share, fuelled by a mature pharmaceutical ecosystem and high concentration of AI technology firms. The United States leads in R&D expenditure, supported by strong government funding through the NIH and favorable venture capital investments. The presence of major pharmaceutical companies and tech giants collaborating on drug discovery platforms creates a robust innovation hub.
Region with highest CAGR:
Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, supported by rapid digitalization and a growing contract research organization (CRO) sector. Countries like China, India, and South Korea are investing heavily in AI infrastructure and bioinformatics to reduce manufacturing costs and accelerate generic drug development. Government initiatives promoting 'AI for Healthcare' are fostering local startup ecosystems and attracting foreign investment.
Key players in the market
Some of the key players in AI Driven Drug Discovery Market include Insilico Medicine, BenevolentAI, Exscientia plc, Recursion Pharmaceuticals, Atomwise Inc., Deep Genomics, Schr?dinger, Inc., Evotec SE, Valo Health, Verge Genomics, Healx, XtalPi, Standigm, Cyclica Inc., and Iktos.
Key Developments:
In March 2026, Insilico Medicine announced a strategic research collaboration with ASKA Pharmaceutical Co., Ltd., a specialized pharmaceutical company with a strong focus on internal medicine, obstetrics, and gynecology. This partnership aims to identify novel therapeutic targets with high drug development potential for challenging gynecological conditions, including endometriosis, uterine fibroids, and adenomyosis, by leveraging Insilico’s proprietary AI-driven target identification engine, PandaOmics.
Components Covered:
All the customers of this report will be entitled to receive one of the following free customization options:
Market Dynamics:
Driver:
Accelerating R&D timelines and cost pressures
The pharmaceutical industry faces immense pressure to reduce the substantial time and financial investment required to bring a drug to market, which traditionally exceeds a decade and costs over $2.6 billion. AI-driven platforms directly address this by automating target identification, predicting drug toxicity early, and optimizing clinical trial designs. Machine learning algorithms can analyze vast datasets in days rather than years, allowing companies to fail unsuccessful candidates faster and focus resources on the most promising assets. This imperative to improve R&D productivity is compelling pharmaceutical giants to integrate AI solutions across their discovery pipelines, transforming operational efficiency.
Restraint:
Data availability and interoperability challenges
The effectiveness of AI models is heavily dependent on the availability of high-quality, standardized, and annotated datasets. However, the biomedical data landscape is often fragmented, consisting of disparate electronic health records, proprietary chemical libraries, and unstructured research papers that lack interoperability. Concerns regarding data privacy, intellectual property rights, and the siloed nature of proprietary datasets further restrict the training of robust algorithms. Without access to comprehensive, clean, and harmonized data, AI models risk generating biased or inaccurate predictions, which limits their full potential and slows down mainstream adoption across the industry.
Opportunity:
Expansion into novel therapeutic modalities and complex diseases
As AI algorithms become more sophisticated, there is a significant opportunity to apply them beyond traditional small molecules to complex modalities such as gene therapies, RNA therapeutics, and antibody-drug conjugates. Generative AI and deep learning are unlocking the ability to design novel biologics and navigate the complexities of multi-target diseases like neurodegeneration and rare genetic disorders. The integration of multi-omics data (genomics, proteomics) with AI is enabling the discovery of entirely new classes of drugs that were previously undruggable. This capability opens vast new revenue streams for AI-focused firms and accelerates the development of cures for historically challenging therapeutic areas.
Threat:
Evolving regulatory and validation frameworks
The 'black box' nature of many AI algorithms poses a significant threat to widespread adoption, as regulatory bodies like the FDA and EMA grapple with how to validate and approve drugs discovered through opaque AI processes. There is currently a lack of standardized guidelines for verifying the safety, efficacy, and reproducibility of AI-generated drug candidates. Uncertainty surrounding intellectual property rights for AI-invented compounds further complicates commercialization strategies. As the market grows, any delays in establishing clear regulatory pathways or failures in AI-predicted candidates during late-stage trials could erode investor confidence and slow market momentum.
Covid-19 Impact
The COVID-19 pandemic served as a catalyst for the AI-driven drug discovery market, as researchers urgently sought rapid solutions. AI platforms were deployed extensively to repurpose existing drugs and design novel antivirals against the SARS-CoV-2 virus, significantly compressing the initial discovery phase. The crisis validated AI’s capability to operate at unprecedented speeds, leading to a surge in venture capital funding and strategic partnerships. However, supply chain disruptions and the redirection of clinical resources initially hampered validation efforts. Post-pandemic, the industry has adopted a more resilient mindset, leveraging the proven success of AI to build robust, agile discovery pipelines for future pandemics and chronic diseases.
The Machine Learning segment is expected to be the largest during the forecast period
The Machine Learning segment is expected to account for the largest market share during the forecast period, due to its foundational role in analyzing complex biological datasets. As the most mature AI technology, ML algorithms are extensively used for pattern recognition in genomics, protein folding, and biomarker identification. Its versatility allows for application across various stages, from target validation to preclinical modeling.
The Pharmaceutical Companies segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the Pharmaceutical Companies segment is predicted to witness the highest growth rate, driven by the urgent need to replenish patent-expired drug portfolios. Major pharma players are aggressively adopting AI to de-risk R&D, streamline operations, and lower the high attrition rates associated with clinical trials. The shift from in-house R&D to hybrid models involving strategic acquisitions of AI-native startups is accelerating adoption.
Region with largest share:
During the forecast period, the North America region is expected to hold the largest market share, fuelled by a mature pharmaceutical ecosystem and high concentration of AI technology firms. The United States leads in R&D expenditure, supported by strong government funding through the NIH and favorable venture capital investments. The presence of major pharmaceutical companies and tech giants collaborating on drug discovery platforms creates a robust innovation hub.
Region with highest CAGR:
Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, supported by rapid digitalization and a growing contract research organization (CRO) sector. Countries like China, India, and South Korea are investing heavily in AI infrastructure and bioinformatics to reduce manufacturing costs and accelerate generic drug development. Government initiatives promoting 'AI for Healthcare' are fostering local startup ecosystems and attracting foreign investment.
Key players in the market
Some of the key players in AI Driven Drug Discovery Market include Insilico Medicine, BenevolentAI, Exscientia plc, Recursion Pharmaceuticals, Atomwise Inc., Deep Genomics, Schr?dinger, Inc., Evotec SE, Valo Health, Verge Genomics, Healx, XtalPi, Standigm, Cyclica Inc., and Iktos.
Key Developments:
In March 2026, Insilico Medicine announced a strategic research collaboration with ASKA Pharmaceutical Co., Ltd., a specialized pharmaceutical company with a strong focus on internal medicine, obstetrics, and gynecology. This partnership aims to identify novel therapeutic targets with high drug development potential for challenging gynecological conditions, including endometriosis, uterine fibroids, and adenomyosis, by leveraging Insilico’s proprietary AI-driven target identification engine, PandaOmics.
Components Covered:
- Software
- Services
- Machine Learning
- Deep Learning
- Natural Language Processing (NLP)
- Generative AI
- Computer Vision
- Other AI Technologies
- Small Molecules
- Large Molecules / Biologics
- Oncology
- Neurodegenerative Diseases
- Cardiovascular Diseases
- Infectious Diseases
- Metabolic Disorders
- Immunology
- Respiratory Diseases
- Other Therapeutic Areas
- Target Identification & Validation
- Hit Identification / Molecule Screening
- Lead Generation
- Lead Optimization
- Drug Repurposing
- Preclinical Testing
- Clinical Trial Optimization
- Pharmaceutical Companies
- Biotechnology Companies
- Contract Research Organizations (CROs)
- Academic & Research Institutes
- Other End Users
- North America
- United States
- Canada
- Mexico
- Europe
- United Kingdom
- Germany
- France
- Italy
- Spain
- Netherlands
- Belgium
- Sweden
- Switzerland
- Poland
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Vietnam
- Rest of Asia Pacific
- South America
- Brazil
- Argentina
- Colombia
- Chile
- Peru
- Rest of South America
- Rest of the World (RoW)
- Middle East
- Saudi Arabia
- United Arab Emirates
- Qatar
- Israel
- Rest of Middle East
- Africa
- South Africa
- Egypt
- Morocco
- Rest of Africa
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
All the customers of this report will be entitled to receive one of the following free customization options:
- Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
- Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
- Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
1 EXECUTIVE SUMMARY
1.1 Market Snapshot and Key Highlights
1.2 Growth Drivers, Challenges, and Opportunities
1.3 Competitive Landscape Overview
1.4 Strategic Insights and Recommendations
2 RESEARCH FRAMEWORK
2.1 Study Objectives and Scope
2.2 Stakeholder Analysis
2.3 Research Assumptions and Limitations
2.4 Research Methodology
2.4.1 Data Collection (Primary and Secondary)
2.4.2 Data Modeling and Estimation Techniques
2.4.3 Data Validation and Triangulation
2.4.4 Analytical and Forecasting Approach
3 MARKET DYNAMICS AND TREND ANALYSIS
3.1 Market Definition and Structure
3.2 Key Market Drivers
3.3 Market Restraints and Challenges
3.4 Growth Opportunities and Investment Hotspots
3.5 Industry Threats and Risk Assessment
3.6 Technology and Innovation Landscape
3.7 Emerging and High-Growth Markets
3.8 Regulatory and Policy Environment
3.9 Impact of COVID-19 and Recovery Outlook
4 COMPETITIVE AND STRATEGIC ASSESSMENT
4.1 Porter's Five Forces Analysis
4.1.1 Supplier Bargaining Power
4.1.2 Buyer Bargaining Power
4.1.3 Threat of Substitutes
4.1.4 Threat of New Entrants
4.1.5 Competitive Rivalry
4.2 Market Share Analysis of Key Players
4.3 Product Benchmarking and Performance Comparison
5 GLOBAL AI DRIVEN DRUG DISCOVERY MARKET, BY COMPONENT
5.1 Software
5.1.1 AI Drug Discovery Platforms
5.1.2 Data Analytics & Modeling Software
5.1.3 Molecular Modeling & Simulation Tools
5.2 Services
5.2.1 AI Consulting Services
5.2.2 Data Processing & Integration Services
5.2.3 Drug Discovery Support Services
6 GLOBAL AI DRIVEN DRUG DISCOVERY MARKET, BY TECHNOLOGY
6.1 Machine Learning
6.2 Deep Learning
6.3 Natural Language Processing (NLP)
6.4 Generative AI
6.5 Computer Vision
6.6 Other AI Technologies
7 GLOBAL AI DRIVEN DRUG DISCOVERY MARKET, BY DRUG TYPE
7.1 Small Molecules
7.2 Large Molecules / Biologics
8 GLOBAL AI DRIVEN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA
8.1 Oncology
8.2 Neurodegenerative Diseases
8.3 Cardiovascular Diseases
8.4 Infectious Diseases
8.5 Metabolic Disorders
8.6 Immunology
8.7 Respiratory Diseases
8.8 Other Therapeutic Areas
9 GLOBAL AI DRIVEN DRUG DISCOVERY MARKET, BY APPLICATION
9.1 Target Identification & Validation
9.2 Hit Identification / Molecule Screening
9.3 Lead Generation
9.4 Lead Optimization
9.5 Drug Repurposing
9.6 Preclinical Testing
9.7 Clinical Trial Optimization
10 GLOBAL AI DRIVEN DRUG DISCOVERY MARKET, BY END USER
10.1 Pharmaceutical Companies
10.2 Biotechnology Companies
10.3 Contract Research Organizations (CROs)
10.4 Academic & Research Institutes
10.5 Other End Users
11 GLOBAL AI DRIVEN DRUG DISCOVERY MARKET, BY GEOGRAPHY
11.1 North America
11.1.1 United States
11.1.2 Canada
11.1.3 Mexico
11.2 Europe
11.2.1 United Kingdom
11.2.2 Germany
11.2.3 France
11.2.4 Italy
11.2.5 Spain
11.2.6 Netherlands
11.2.7 Belgium
11.2.8 Sweden
11.2.9 Switzerland
11.2.10 Poland
11.2.11 Rest of Europe
11.3 Asia Pacific
11.3.1 China
11.3.2 Japan
11.3.3 India
11.3.4 South Korea
11.3.5 Australia
11.3.6 Indonesia
11.3.7 Thailand
11.3.8 Malaysia
11.3.9 Singapore
11.3.10 Vietnam
11.3.11 Rest of Asia Pacific
11.4 South America
11.4.1 Brazil
11.4.2 Argentina
11.4.3 Colombia
11.4.4 Chile
11.4.5 Peru
11.4.6 Rest of South America
11.5 Rest of the World (RoW)
11.5.1 Middle East
11.5.1.1 Saudi Arabia
11.5.1.2 United Arab Emirates
11.5.1.3 Qatar
11.5.1.4 Israel
11.5.1.5 Rest of Middle East
11.5.2 Africa
11.5.2.1 South Africa
11.5.2.2 Egypt
11.5.2.3 Morocco
11.5.2.4 Rest of Africa
12 STRATEGIC MARKET INTELLIGENCE
12.1 Industry Value Network and Supply Chain Assessment
12.2 White-Space and Opportunity Mapping
12.3 Product Evolution and Market Life Cycle Analysis
12.4 Channel, Distributor, and Go-to-Market Assessment
13 INDUSTRY DEVELOPMENTS AND STRATEGIC INITIATIVES
13.1 Mergers and Acquisitions
13.2 Partnerships, Alliances, and Joint Ventures
13.3 New Product Launches and Certifications
13.4 Capacity Expansion and Investments
13.5 Other Strategic Initiatives
14 COMPANY PROFILES
14.1 Insilico Medicine
14.2 BenevolentAI
14.3 Exscientia plc
14.4 Recursion Pharmaceuticals
14.5 Atomwise Inc.
14.6 Deep Genomics
14.7 Schr?dinger, Inc.
14.8 Evotec SE
14.9 Valo Health
14.10 Verge Genomics
14.11 Healx
14.12 XtalPi
14.13 Standigm
14.14 Cyclica Inc.
14.15 Iktos
1.1 Market Snapshot and Key Highlights
1.2 Growth Drivers, Challenges, and Opportunities
1.3 Competitive Landscape Overview
1.4 Strategic Insights and Recommendations
2 RESEARCH FRAMEWORK
2.1 Study Objectives and Scope
2.2 Stakeholder Analysis
2.3 Research Assumptions and Limitations
2.4 Research Methodology
2.4.1 Data Collection (Primary and Secondary)
2.4.2 Data Modeling and Estimation Techniques
2.4.3 Data Validation and Triangulation
2.4.4 Analytical and Forecasting Approach
3 MARKET DYNAMICS AND TREND ANALYSIS
3.1 Market Definition and Structure
3.2 Key Market Drivers
3.3 Market Restraints and Challenges
3.4 Growth Opportunities and Investment Hotspots
3.5 Industry Threats and Risk Assessment
3.6 Technology and Innovation Landscape
3.7 Emerging and High-Growth Markets
3.8 Regulatory and Policy Environment
3.9 Impact of COVID-19 and Recovery Outlook
4 COMPETITIVE AND STRATEGIC ASSESSMENT
4.1 Porter's Five Forces Analysis
4.1.1 Supplier Bargaining Power
4.1.2 Buyer Bargaining Power
4.1.3 Threat of Substitutes
4.1.4 Threat of New Entrants
4.1.5 Competitive Rivalry
4.2 Market Share Analysis of Key Players
4.3 Product Benchmarking and Performance Comparison
5 GLOBAL AI DRIVEN DRUG DISCOVERY MARKET, BY COMPONENT
5.1 Software
5.1.1 AI Drug Discovery Platforms
5.1.2 Data Analytics & Modeling Software
5.1.3 Molecular Modeling & Simulation Tools
5.2 Services
5.2.1 AI Consulting Services
5.2.2 Data Processing & Integration Services
5.2.3 Drug Discovery Support Services
6 GLOBAL AI DRIVEN DRUG DISCOVERY MARKET, BY TECHNOLOGY
6.1 Machine Learning
6.2 Deep Learning
6.3 Natural Language Processing (NLP)
6.4 Generative AI
6.5 Computer Vision
6.6 Other AI Technologies
7 GLOBAL AI DRIVEN DRUG DISCOVERY MARKET, BY DRUG TYPE
7.1 Small Molecules
7.2 Large Molecules / Biologics
8 GLOBAL AI DRIVEN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA
8.1 Oncology
8.2 Neurodegenerative Diseases
8.3 Cardiovascular Diseases
8.4 Infectious Diseases
8.5 Metabolic Disorders
8.6 Immunology
8.7 Respiratory Diseases
8.8 Other Therapeutic Areas
9 GLOBAL AI DRIVEN DRUG DISCOVERY MARKET, BY APPLICATION
9.1 Target Identification & Validation
9.2 Hit Identification / Molecule Screening
9.3 Lead Generation
9.4 Lead Optimization
9.5 Drug Repurposing
9.6 Preclinical Testing
9.7 Clinical Trial Optimization
10 GLOBAL AI DRIVEN DRUG DISCOVERY MARKET, BY END USER
10.1 Pharmaceutical Companies
10.2 Biotechnology Companies
10.3 Contract Research Organizations (CROs)
10.4 Academic & Research Institutes
10.5 Other End Users
11 GLOBAL AI DRIVEN DRUG DISCOVERY MARKET, BY GEOGRAPHY
11.1 North America
11.1.1 United States
11.1.2 Canada
11.1.3 Mexico
11.2 Europe
11.2.1 United Kingdom
11.2.2 Germany
11.2.3 France
11.2.4 Italy
11.2.5 Spain
11.2.6 Netherlands
11.2.7 Belgium
11.2.8 Sweden
11.2.9 Switzerland
11.2.10 Poland
11.2.11 Rest of Europe
11.3 Asia Pacific
11.3.1 China
11.3.2 Japan
11.3.3 India
11.3.4 South Korea
11.3.5 Australia
11.3.6 Indonesia
11.3.7 Thailand
11.3.8 Malaysia
11.3.9 Singapore
11.3.10 Vietnam
11.3.11 Rest of Asia Pacific
11.4 South America
11.4.1 Brazil
11.4.2 Argentina
11.4.3 Colombia
11.4.4 Chile
11.4.5 Peru
11.4.6 Rest of South America
11.5 Rest of the World (RoW)
11.5.1 Middle East
11.5.1.1 Saudi Arabia
11.5.1.2 United Arab Emirates
11.5.1.3 Qatar
11.5.1.4 Israel
11.5.1.5 Rest of Middle East
11.5.2 Africa
11.5.2.1 South Africa
11.5.2.2 Egypt
11.5.2.3 Morocco
11.5.2.4 Rest of Africa
12 STRATEGIC MARKET INTELLIGENCE
12.1 Industry Value Network and Supply Chain Assessment
12.2 White-Space and Opportunity Mapping
12.3 Product Evolution and Market Life Cycle Analysis
12.4 Channel, Distributor, and Go-to-Market Assessment
13 INDUSTRY DEVELOPMENTS AND STRATEGIC INITIATIVES
13.1 Mergers and Acquisitions
13.2 Partnerships, Alliances, and Joint Ventures
13.3 New Product Launches and Certifications
13.4 Capacity Expansion and Investments
13.5 Other Strategic Initiatives
14 COMPANY PROFILES
14.1 Insilico Medicine
14.2 BenevolentAI
14.3 Exscientia plc
14.4 Recursion Pharmaceuticals
14.5 Atomwise Inc.
14.6 Deep Genomics
14.7 Schr?dinger, Inc.
14.8 Evotec SE
14.9 Valo Health
14.10 Verge Genomics
14.11 Healx
14.12 XtalPi
14.13 Standigm
14.14 Cyclica Inc.
14.15 Iktos
LIST OF TABLES
Table 1 Global AI Driven Drug Discovery Market Outlook, By Region (2023-2034) ($MN)
Table 2 Global AI Driven Drug Discovery Market Outlook, By Component (2023-2034) ($MN)
Table 3 Global AI Driven Drug Discovery Market Outlook, By Software (2023-2034) ($MN)
Table 4 Global AI Driven Drug Discovery Market Outlook, By AI Drug Discovery Platforms (2023-2034) ($MN)
Table 5 Global AI Driven Drug Discovery Market Outlook, By Data Analytics & Modeling Software (2023-2034) ($MN)
Table 6 Global AI Driven Drug Discovery Market Outlook, By Molecular Modeling & Simulation Tools (2023-2034) ($MN)
Table 7 Global AI Driven Drug Discovery Market Outlook, By Services (2023-2034) ($MN)
Table 8 Global AI Driven Drug Discovery Market Outlook, By AI Consulting Services (2023-2034) ($MN)
Table 9 Global AI Driven Drug Discovery Market Outlook, By Data Processing & Integration Services (2023-2034) ($MN)
Table 10 Global AI Driven Drug Discovery Market Outlook, By Drug Discovery Support Services (2023-2034) ($MN)
Table 11 Global AI Driven Drug Discovery Market Outlook, By Technology (2023-2034) ($MN)
Table 12 Global AI Driven Drug Discovery Market Outlook, By Machine Learning (2023-2034) ($MN)
Table 13 Global AI Driven Drug Discovery Market Outlook, By Deep Learning (2023-2034) ($MN)
Table 14 Global AI Driven Drug Discovery Market Outlook, By Natural Language Processing (NLP) (2023-2034) ($MN)
Table 15 Global AI Driven Drug Discovery Market Outlook, By Generative AI (2023-2034) ($MN)
Table 16 Global AI Driven Drug Discovery Market Outlook, By Computer Vision (2023-2034) ($MN)
Table 17 Global AI Driven Drug Discovery Market Outlook, By Other AI Technologies (2023-2034) ($MN)
Table 18 Global AI Driven Drug Discovery Market Outlook, By Drug Type (2023-2034) ($MN)
Table 19 Global AI Driven Drug Discovery Market Outlook, By Small Molecules (2023-2034) ($MN)
Table 20 Global AI Driven Drug Discovery Market Outlook, By Large Molecules / Biologics (2023-2034) ($MN)
Table 21 Global AI Driven Drug Discovery Market Outlook, By Therapeutic Area (2023-2034) ($MN)
Table 22 Global AI Driven Drug Discovery Market Outlook, By Oncology (2023-2034) ($MN)
Table 23 Global AI Driven Drug Discovery Market Outlook, By Neurodegenerative Diseases (2023-2034) ($MN)
Table 24 Global AI Driven Drug Discovery Market Outlook, By Cardiovascular Diseases (2023-2034) ($MN)
Table 25 Global AI Driven Drug Discovery Market Outlook, By Infectious Diseases (2023-2034) ($MN)
Table 26 Global AI Driven Drug Discovery Market Outlook, By Metabolic Disorders (2023-2034) ($MN)
Table 27 Global AI Driven Drug Discovery Market Outlook, By Immunology (2023-2034) ($MN)
Table 28 Global AI Driven Drug Discovery Market Outlook, By Respiratory Diseases (2023-2034) ($MN)
Table 29 Global AI Driven Drug Discovery Market Outlook, By Other Therapeutic Areas (2023-2034) ($MN)
Table 30 Global AI Driven Drug Discovery Market Outlook, By Application (2023-2034) ($MN)
Table 31 Global AI Driven Drug Discovery Market Outlook, By Target Identification & Validation (2023-2034) ($MN)
Table 32 Global AI Driven Drug Discovery Market Outlook, By Hit Identification / Molecule Screening (2023-2034) ($MN)
Table 33 Global AI Driven Drug Discovery Market Outlook, By Lead Generation (2023-2034) ($MN)
Table 34 Global AI Driven Drug Discovery Market Outlook, By Lead Optimization (2023-2034) ($MN)
Table 35 Global AI Driven Drug Discovery Market Outlook, By Drug Repurposing (2023-2034) ($MN)
Table 36 Global AI Driven Drug Discovery Market Outlook, By Preclinical Testing (2023-2034) ($MN)
Table 37 Global AI Driven Drug Discovery Market Outlook, By Clinical Trial Optimization (2023-2034) ($MN)
Table 38 Global AI Driven Drug Discovery Market Outlook, By End User (2023-2034) ($MN)
Table 39 Global AI Driven Drug Discovery Market Outlook, By Pharmaceutical Companies (2023-2034) ($MN)
Table 40 Global AI Driven Drug Discovery Market Outlook, By Biotechnology Companies (2023-2034) ($MN)
Table 41 Global AI Driven Drug Discovery Market Outlook, By Contract Research Organizations (CROs) (2023-2034) ($MN)
Table 42 Global AI Driven Drug Discovery Market Outlook, By Academic & Research Institutes (2023-2034) ($MN)
Table 43 Global AI Driven Drug Discovery Market Outlook, By Other End Users (2023-2034) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) are also represented in the same manner as above.
Table 1 Global AI Driven Drug Discovery Market Outlook, By Region (2023-2034) ($MN)
Table 2 Global AI Driven Drug Discovery Market Outlook, By Component (2023-2034) ($MN)
Table 3 Global AI Driven Drug Discovery Market Outlook, By Software (2023-2034) ($MN)
Table 4 Global AI Driven Drug Discovery Market Outlook, By AI Drug Discovery Platforms (2023-2034) ($MN)
Table 5 Global AI Driven Drug Discovery Market Outlook, By Data Analytics & Modeling Software (2023-2034) ($MN)
Table 6 Global AI Driven Drug Discovery Market Outlook, By Molecular Modeling & Simulation Tools (2023-2034) ($MN)
Table 7 Global AI Driven Drug Discovery Market Outlook, By Services (2023-2034) ($MN)
Table 8 Global AI Driven Drug Discovery Market Outlook, By AI Consulting Services (2023-2034) ($MN)
Table 9 Global AI Driven Drug Discovery Market Outlook, By Data Processing & Integration Services (2023-2034) ($MN)
Table 10 Global AI Driven Drug Discovery Market Outlook, By Drug Discovery Support Services (2023-2034) ($MN)
Table 11 Global AI Driven Drug Discovery Market Outlook, By Technology (2023-2034) ($MN)
Table 12 Global AI Driven Drug Discovery Market Outlook, By Machine Learning (2023-2034) ($MN)
Table 13 Global AI Driven Drug Discovery Market Outlook, By Deep Learning (2023-2034) ($MN)
Table 14 Global AI Driven Drug Discovery Market Outlook, By Natural Language Processing (NLP) (2023-2034) ($MN)
Table 15 Global AI Driven Drug Discovery Market Outlook, By Generative AI (2023-2034) ($MN)
Table 16 Global AI Driven Drug Discovery Market Outlook, By Computer Vision (2023-2034) ($MN)
Table 17 Global AI Driven Drug Discovery Market Outlook, By Other AI Technologies (2023-2034) ($MN)
Table 18 Global AI Driven Drug Discovery Market Outlook, By Drug Type (2023-2034) ($MN)
Table 19 Global AI Driven Drug Discovery Market Outlook, By Small Molecules (2023-2034) ($MN)
Table 20 Global AI Driven Drug Discovery Market Outlook, By Large Molecules / Biologics (2023-2034) ($MN)
Table 21 Global AI Driven Drug Discovery Market Outlook, By Therapeutic Area (2023-2034) ($MN)
Table 22 Global AI Driven Drug Discovery Market Outlook, By Oncology (2023-2034) ($MN)
Table 23 Global AI Driven Drug Discovery Market Outlook, By Neurodegenerative Diseases (2023-2034) ($MN)
Table 24 Global AI Driven Drug Discovery Market Outlook, By Cardiovascular Diseases (2023-2034) ($MN)
Table 25 Global AI Driven Drug Discovery Market Outlook, By Infectious Diseases (2023-2034) ($MN)
Table 26 Global AI Driven Drug Discovery Market Outlook, By Metabolic Disorders (2023-2034) ($MN)
Table 27 Global AI Driven Drug Discovery Market Outlook, By Immunology (2023-2034) ($MN)
Table 28 Global AI Driven Drug Discovery Market Outlook, By Respiratory Diseases (2023-2034) ($MN)
Table 29 Global AI Driven Drug Discovery Market Outlook, By Other Therapeutic Areas (2023-2034) ($MN)
Table 30 Global AI Driven Drug Discovery Market Outlook, By Application (2023-2034) ($MN)
Table 31 Global AI Driven Drug Discovery Market Outlook, By Target Identification & Validation (2023-2034) ($MN)
Table 32 Global AI Driven Drug Discovery Market Outlook, By Hit Identification / Molecule Screening (2023-2034) ($MN)
Table 33 Global AI Driven Drug Discovery Market Outlook, By Lead Generation (2023-2034) ($MN)
Table 34 Global AI Driven Drug Discovery Market Outlook, By Lead Optimization (2023-2034) ($MN)
Table 35 Global AI Driven Drug Discovery Market Outlook, By Drug Repurposing (2023-2034) ($MN)
Table 36 Global AI Driven Drug Discovery Market Outlook, By Preclinical Testing (2023-2034) ($MN)
Table 37 Global AI Driven Drug Discovery Market Outlook, By Clinical Trial Optimization (2023-2034) ($MN)
Table 38 Global AI Driven Drug Discovery Market Outlook, By End User (2023-2034) ($MN)
Table 39 Global AI Driven Drug Discovery Market Outlook, By Pharmaceutical Companies (2023-2034) ($MN)
Table 40 Global AI Driven Drug Discovery Market Outlook, By Biotechnology Companies (2023-2034) ($MN)
Table 41 Global AI Driven Drug Discovery Market Outlook, By Contract Research Organizations (CROs) (2023-2034) ($MN)
Table 42 Global AI Driven Drug Discovery Market Outlook, By Academic & Research Institutes (2023-2034) ($MN)
Table 43 Global AI Driven Drug Discovery Market Outlook, By Other End Users (2023-2034) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) are also represented in the same manner as above.
